PROJECT SUMMARY – Abramson Cancer Center
The Abramson Cancer Center (ACC) at the University of Pennsylvania is one of the oldest NCI-Designated
Comprehensive Cancer Centers. The ACC serves an ethnically and economically diverse catchment area – 12
contiguous counties in Pennsylvania, New Jersey, and Delaware, with approximately 7 million residents.
Residents in our catchment area face significantly higher rates of cancer incidence than the rest of the country.
Through integrated, dynamic, and high-impact Research Programs pursuing basic, clinical, and population-
based research, the ACC fosters pioneering scientific discoveries and facilitates the translation of these
discoveries into clinical practice, transforming paradigms of patient-centered cancer care and cancer control.
ACC provides extraordinary cancer care at three Penn Medicine adult hospitals and Children's Hospital of
Philadelphia. The ACC is further enhanced by being part of the powerful academic ecosystem of the University
of Pennsylvania. The ACC mission is to reduce the burden of cancer throughout our catchment area, the
nation, and the world through uniquely integrated, productive, and comprehensive research efforts. Our vision
is to exemplify an exceptional science-driven, patient-focused comprehensive cancer center with deep and
lasting impact. The ACC has 324 members, nine Research Programs, nine Shared Resources, and robust
teams for Community Outreach and Engagement, Clinical Protocol and Data Management, Protocol Review
and Monitoring Systems, Cancer Research Training and Education, and Administration. In the current funding
period, ACC members published 4,052 manuscripts and enrolled more than 22,000 subjects on interventional
trials and more than 37,000 subjects on non-interventional trials. ACC members hold $170.1M in annual direct
funds, of which $103.2M comes from the NIH and $59.2M from the NCI. ACC members hold 267 R01-
equivalents. Notable strengths of the ACC include extraordinary intellectual capital, a uniquely collaborative
culture that drives translational research, a balanced and strong research portfolio, deep commitment to our
catchment area, and a modern and expanding cancer clinical enterprise for the care of adults and children.
Chief accomplishments in the current funding period include transformative science in immunology, cell
biology, germline genetics, and epigenetics; clinical trials with impact ranging from bench-to-beside discovery
to multiple FDA approvals, including development, translation, and FDA approval of CAR T cells as the first
cancer gene therapy; novel approaches in proton radiation and molecular imaging; nation-leading efforts in
smoking cessation and HPV vaccination; doubling of Black subjects' participation in clinical trials; and
leadership driving new health policy around smoking and sugary beverages. By leveraging new Institutional,
philanthropic, and other resources, the ACC continues to innovate to reduce the burden of cancer in our
catchment area and beyond, relentlessly working in a comprehensive and rigorous fashion to improve the lives
of cancer patients and those at risk.